论文部分内容阅读
[目的]探讨血必净注射液对结肠癌患者术后细胞免疫功能的影响及其临床意义。[方法]将47例结肠癌患者随机分为2组。对照组23例,给予常规手术、支持治疗;治疗组24例,在常规治疗的基础上术后早期加用血必净注射液治疗。采用双抗体标记流式细胞分析技术测定患者术前1d、术后1d和5d的外周血T淋巴细胞亚群CD4+,CD8+的百分率及CD4+/CD8+比值。[结果]2组患者术后1d和5d时,外周血CD4+和CD4+/CD8+比值均较手术前明显下降(均P<0.05)。术后5d时,治疗组外周血CD4+和CD4+/CD8+比值明显回升,与对照组比较差异有统计学意义(均P<0.05)。[结论]结肠癌患者术后在常规治疗的基础上早期使用血必净注射液,能较快纠正T细胞辅助/抑制免疫调节网络的紊乱或抑制,有助于维持细胞免疫调节功能的平衡。
[Objective] To investigate the effect of Xuebijing Injection on cellular immune function in patients with colon cancer and its clinical significance. [Method] 47 patients with colon cancer were randomly divided into two groups. The control group of 23 cases, given conventional surgery, supportive treatment; treatment group of 24 patients, based on conventional treatment after the early use of Xuebijing injection. The percentage of CD4 +, CD8 + and the ratio of CD4 + / CD8 + in peripheral blood T lymphocyte subsets on the first day, the day before operation and the day after operation were measured by double antibody labeling flow cytometry. [Results] The ratio of CD4 + and CD4 + / CD8 + in the peripheral blood of the two groups were significantly decreased at 1 and 5 days after operation (all P <0.05). At 5 days after operation, the ratio of CD4 + and CD4 + / CD8 + in the peripheral blood of the treated group rose significantly compared with the control group (all P <0.05). [Conclusion] The early use of Xuebijing Injection on the basis of routine treatment after colon cancer patients can quickly correct the disorder or inhibition of T cell auxiliary / suppression immune regulatory network and help to maintain the balance of cellular immune regulatory function.